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Abstract
Background: In patients with intracranial large vessel arterial occlusion, ipsilateral extracranial carotid artery
occlusions or near-occlusions pose a significant hurdle in endovascular management of acute ischaemic stroke.
Stenting of the carotid lesion may be beneficial in this situation to provide a stable access for introducing catheters
through the carotid lesion into the intracranial vasculature and the target occlusion. Furthermore, carotid stenting
may ensure ample blood flow for wash-out of clot material and reperfusion of the ischaemic penumbral tissue.
However, antiplatelet therapy administered to prevent stent thrombosis and sudden increase in blood flow after
reopening of the carotid lesion may increase the risk for intracranial haemorrhagic complications. This review aims
to assess the benefits and harms of carotid stenting vs. no stenting assisting thrombectomy for acute ischaemic
stroke.
Methods: International and regional electronic databases will be searched to identify eligible randomised clinical
trials. To identify further published, unpublished, or on-going and planned trials searches of Google Scholar,
Worldwide Food and Drug Administrations, Worldwide Medicines Agencies, company homepages, reference lists,
conference proceedings, and the Science Citation Index cited reference search index will be conducted.
Manufacturers of relevant interventional equipment, authors, colleagues, and researchers active in the field will be
contacted. No language restrictions will be applied to these searches. Randomised clinical trials will be included for
assessing benefits and harms and quasi-randomised studies, and observational studies will be included for assessing
harms of the intervention. Meta-analyses will be performed according to the recommendations of the Cochrane
Handbook for Systematic Reviews of Interventions, and Trial Sequential Analyses will be conducted to control the
risk of random errors and prevent premature statements of superiority of the experimental or control intervention
or premature statement of futility. The quality of the evidence will be evaluated with the Grading of
Recommendations Assessment, Development, and Evaluation.
Discussion: This systematic review of carotid stenting in endovascular management of acute ischaemic stroke in
patients with concomitant extracranial carotid lesions and intracranial embolism will assess benefits and harms of
this intervention and assesses whether carotid stenting should be encouraged or avoided in acute ischaemic stroke
and identify targets for further research.
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Background
Description of the condition
Acute ischaemic stroke is the leading cause of ac-
quired long-term disability and the fourth most com-
mon cause of death [1]. The severity of acute
ischaemic stroke varies from minor focal neurological
deficits over life-threatening hemispheric syndromes
to death. Due to the high oxygen requirement of the
brain tissue, expeditious management is crucial for re-
versal of ischaemia and successful salvage of the tis-
sue at risk [2]. Large intracranial emboli cause severe
ischaemic stroke with poor outcome and poor re-
sponse to medical therapy alone due to the large clot
burden [3, 4]. A particular harmful configuration of
large vessel occlusions is the carotid artery occlusion
or near-occlusion in combination with intracranial
embolism. This configuration is suggested to be the
cause of acute ischaemic stroke in up to 20 to 30% of
patients with large vessel occlusions [5–8]. The ca-
rotid occlusion or near-occlusion is caused by an ar-
terial dissection or atherosclerotic plaque. It releases
an often large clot into the intracranial vasculature
causing severe stroke symptoms. Usually, carotid oc-
clusions or near-occlusions can be compensated
haemodynamically via the circle of Willis [9], but not
in the case of an embolus lodged in the middle cere-
bral artery [10].
Administration of intravenous recombinant tissue
plasminogen activator (iv-rtPA) is currently the rec-
ommended first-line treatment for acute ischaemic
stroke if it can be administered within 4.5 h of symp-
tom onset [11, 12]. However, in patients suffering
moderate to severe stroke from acute large vessel oc-
clusions, iv-rtPA is often ineffective [4, 13]. Cohort
studies suggest that iv-rtPA administration alone only
leads to clinical improvement in 20 to 30% of patients
with concomitant extracranial carotid and intracranial
occlusions [13–16]. Carotid endarterectomy is not the
preferred option, since surgery would only address
the extracranial carotid lesion without access to the
intracranial occlusion. Furthermore, open surgery is
relatively contraindicated with recent iv-rtPA adminis-
tration, as open surgery has a high complication rate
in the very urgent phase of acute stroke [17], and is
not advocated to repair carotid dissections [18].
Endovascular therapy with mechanical thrombectomy
or intra-arterial thrombolysis of large intracranial occlu-
sions have long been considered a possible adjuvant to
medical therapy although initial randomised controlled
trials failed to reveal clear benefits [19–21]. However, in
the past year, five randomised controlled trials have
shown superior outcomes of endovascular therapy com-
pared with medical therapy alone [7, 8, 22–25]. This
leads to thrombectomy of large intracranial occlusions
being recommended in the American Heart Association
guidelines for acute ischaemic stroke therapy with the
highest evidence (class I, level of evidence A) [26]. The
primary target of endovascular therapy in patients with
carotid lesions and concomitant intracranial embolism is
removal of the intracranial clot material. Endovascular
therapy has the advantage of being able to access the
intracranial thrombus either directly through the ipsilat-
eral carotid lesion or indirectly via collateral vessels [27].
The indirect access via contralateral vessels is technically
challenging and depends on favourable anatomy of the
circle of Willis. The direct access is more straightfor-
ward but bares the risks with penetrating the wire
through a carotid occlusion or near-occlusion unable to
predict passage within the true lumen resulting in dis-
section of the vessel wall as well as dislodgement of
thrombotic material distal to the carotid lesion.
Description of the intervention
The concerns of the direct access approach in endovas-
cular management of acute ischaemic stroke can to
some extent be compensated by carotid stent-assisted
angioplasty [28]. A carotid stent can easily be provided
through the catheters used for mechanical thrombec-
tomy [10, 29–36]. However, introduction into the carotid
lesion may pose an obstacle if the carotid artery is oc-
cluded or severely stenotic. In this case, the carotid le-
sion may need to be balloon pre-dilated with a balloon
catheter to ensure adequate lumen for traversal of the
stent through the carotid lesion [10, 29–36]. Carotid
stents are mostly self-expanding which means they ex-
pand to a pre-specified diameter when subjected to the
heat inside a vessel. However, some carotid lesions are
so dense that the carotid stent needs balloon post-
dilatation to ensure adequate lumen inside and flow
through the stent.
To prevent in-stent thrombosis, antithrombotic ther-
apy is needed. To our knowledge, no guideline exists on
the optimal antithrombotic regimen for carotid stenting
in endovascular management of acute ischaemic stroke,
and patients are treated on a patient-by-patient basis
[37]. Most centres seem to favour administration of
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mono- or dual antiplatelet therapy immediately after
stent placement and continue with dual antiplatelet ther-
apy after intracerebral haemorrhage has been excluded
after the procedure [10, 29, 33, 35, 36].
How the intervention might work
Carotid stenting may be beneficial in acute ischaemic
stroke treatment because deployment of a stent with or
without angioplasty establishes immediate patency of the
carotid lesion preventing vessel recoil and secures con-
tinuous catheter access to the intracranial vessels. It sta-
bilises and protects the endothelium preventing
iatrogenic dissection of the vessel wall. Furthermore,
acute stenting ensures ample blood flow to the intracra-
nial vasculature, especially in case of contralateral ca-
rotid lesions or unfavourable anatomy of the circle of
Willis, and may assist intracranial recanalisation [37].
Other advantages of acute carotid stenting include acute
prevention of recurrent thrombus formation and embol-
ism from the carotid lesion, which is suggested to occur
in up to 16% of patients within 24 h [38], and avoidance
of a subacute procedure to prevent recurrent ischaemic
events [17, 39].
Carotid stenting in the acute ischaemic stroke setting
is, however, not without concerns. Immediate dual anti-
platelet therapy already administered during the proced-
ure is required to prevent acute stent thrombosis [40].
Potent aggressive antiplatelet therapy may increase the
risk of haemorrhagic stroke as well as procedural bleed-
ing complications [41, 42]—especially following recent
iv-rtPA administration [43]. Furthermore, increased
cerebral blood flow, seen in patients with recanalisation
of chronic carotid occlusions or near-occlusions, may
induce the cerebral hyper-perfusion syndrome and risk
intracerebral haemorrhage [44]. Finally, if met with diffi-
culties, preparatory carotid stenting may delay intracra-
nial revascularisation [32, 33].
Why it is important to do this review?
To our knowledge, only observational studies have
assessed this important topic [37]. All of these patient
series seem to report reasonable benefits and safety
[10, 29–36]. A systematic review will provide a thor-
ough assessment of the evidence for this intervention.
Because of the before mentioned risks of carotid
stenting in acute ischaemic stroke, this review is im-
portant to assess whether carotid stenting in endovas-
cular therapy is beneficial and safe or whether carotid
stenting should be avoided in the acute ischaemic
stroke setting whenever possible.
Objectives
The aims of this study are to assess the benefits and
harms of acute extracranial carotid artery stenting versus
no stenting in patients with acute ischaemic stroke
caused by an extracranial carotid occlusion or near-




This protocol follows the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses Protocol 2015
(PRISMA-P, Additional file 1) and is registered on
PROSPERO with CRD42016033346.
Criteria for considering studies for this review
Types of studies
This review will include randomised clinical trials for as-
sessments of benefits and harms and quasi-randomised
studies and observational studies for assessments of
harms of the intervention.
Types of participants
Participants will be adults (≥18 years) with acute ischae-
mic stroke caused by a carotid artery occlusion or near-
occlusion with concomitant ipsilateral embolism to a
major intracranial vessel. Intracranial and extracranial
occlusions or near-occlusions need to be identified on
CT angiography, MR angiography, or duplex sonography
and confirmed on digital subtraction angiography. Par-
ticipants need to be treated within 6 h of symptom
onset.
Types of interventions
The experimental group will be patients who were ran-
domised to undergo extracranial carotid stenting within
the same procedure as the intracranial thrombectomy.
Carotid stenting may be performed before or after intra-
cranial thrombectomy using any endovascular stent
device.
The comparison group will be patients who were
randomised to avoid carotid stent deployment. The
comparison group may undergo carotid angioplasty
without stenting, patent artery occlusion of the
carotid artery after successful thrombectomy, or no
carotid intervention within the same procedure as
intracranial thrombectomy.
Co-interventions will be allowed if they are used
equally in both the intervention and comparison
groups. However, co-interventions (such as pre- or
post-dilatation of the carotid artery to facilitate stent
deployment) that are generally regarded as a pre-
requisite for the intervention are accepted as an inte-
grated part of the experimental intervention.
Antiplatelet therapy is administered within the endo-
vascular procedure following stent deployment in
most patients of the intervention group while this is
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not the case for the comparison group and patients
with successful carotid stenting have tightly con-
trolled and treated mean arterial blood pressure typ-
ically not exceeding 100 mmHg after the procedure.
These co-interventions will be allowed as an inte-
grated part of the experimental intervention although
they are not used equal in both groups of a trial.
Types of outcome measures
Outcomes will be assessed after 3 months (primary
outcome time point) and at maximal follow-up.
Primary outcomes
– All-cause mortality
– Dependent clinical appearance measured as a score
on the modified Rankin Scale of 3 or more
– Serious adverse events defined as any untoward
medical occurrence that is life threatening, results in
death or persistent or significant disability, or any
other event that may have jeopardised the
participant or require intervention to prevent it [45]
Secondary outcomes
– Quality of life
– Non-serious adverse events
Exploratory outcomes
– Haemorrhagic complications (symptomatic/
asymptomatic)
– Periprocedural embolic events into new territory
– Recurrent ipsilateral ischaemic stroke during
follow-up
Search methods for identification of studies
Electronic searches
The searches will be performed in cooperation with a
Trials Search Coordinator from the Copenhagen
Trial Unit and will include the following electronic
databases:





– Stroke Trials Directory (www.strokecenter.org/trials)
– Clinicaltrials.gov (www.clinicaltrials.gov)
– Current controlled trials (www.controlled-trials.com)
– World Health Organisation’s International Clinical
Trials Registry Platform (http://apps.who.int/
trialsearch/Default.aspx)
Regional databases
– African Index Medicus (http://
indexmedicus.afro.who.int/)
– Australasian Medical Index (http://www.nla.gov.au/
australasian-medical-index, http://
www.informit.com.au/health.html)
– Chinese Biomedical Literature Database (CBM)
(in Chinese) (http://www.imicams.ac.cn/)












– Western Pacific Region Index Medicus (http://
www.wprim.org/)
The initial draft for the electronic database search
presented in MEDLINE (Ovid SP) format:
1. exp Stents/
2. ((carotid and stent*) or CAS).mp.
3. exp Thrombectomy/
4. (thrombectom* or thrombolys*).mp.
5. 1 or 2
6. 3 or 4
7. 5 and 6
8. exp Brain Ischemia/
9. exp Carotid Stenosis/
10.(stroke or isch*emi* or (carotid and (occlusion or near-
occlusion or stenos* or obstruct*)) or apople*).mp.
11.8 or 9 or 10
12.7 and 11
Searching other resources
To identify further published, unpublished, or on-going
and planned trials, the following measures will be taken:
– Search Google Scholar
– American Food and Drug Administration (FDA)
– European Medicines Agency (EMA)
– Health Canada (http://www.hc-sc.gc.ca/index-
eng.php)
– Australian Therapeutic Goods Administration (TGA
https://www.tga.gov.au/)
– China Food and Drug Administration (CFDA http://
eng.sfda.gov.cn/)
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– Brazilian Health Surveillance Agency (ANVISA
http://portal.anvisa.gov.br/)
– Mexican Federal Commission for the Protection
against Sanitary Risk (COFEPRIS http://
www.cofepris.gob.mx/Paginas/Idiomas/Ingles.aspx)
– Argentinian National Administration of Drugs,
Foodstuffs and Medical Technology (ANMAT
http://www.anmat.gov.ar/principal_en.asp)
– Columbian National Food and Drug Surveillance
Institue (INVIMA https://www.invima.gov.co/)
– Thailand Food and Drug Administration (TFDA
http://www.fda.moph.go.th/eng/index.stm)
– Taiwan Food and Drug Administration (TFDA
http://www.fda.gov.tw/EN/)
– Singapore Health Sciences Authority (HAS http://
www.hsa.gov.sg/content/hsa/en.html)
– Japanese Pharmaceuticals and Medical Devices
Agency (PMDA http://www.pmda.go.jp/english/
index.html)
– South Korea Ministry of Food and Drug Safety
(MFDS http://www.mfds.go.kr/eng/index.do)
– Indian Central Drugs Standard Control Organisation
(http://cdsco.nic.in/forms/
contentpage1.aspx?lid=1423)
– Home pages of companies producing devices for the
interventions
– Screening reference lists of relevant trials
– Contact manufacturers of relevant interventional
equipment
– Contact authors, colleagues, and researchers active
in the field
– Identify and hand-search the proceedings of relevant
conferences
– Use the Science Citation Index Cited Reference
search for forward tracking of relevant references
No language restrictions will be applied to the
searches, and translations of potentially relevant non-
English language papers will be obtained.
Data collection and analysis
Selection of studies
Two review authors (Henrik Steglich-Arnholm and Derk
W. Krieger) will independently screen titles and ab-
stracts identified by the searches. Henrik Steglich-
Arnholm will be responsible for obtaining full paper
copies of eligible trials and translation into English if ne-
cessary. Henrik Steglich-Arnholm, Derk W. Krieger, and
Marcus Holtmannspötter will assess the full paper cop-
ies for inclusion into the review. In case of disagree-
ments regarding which papers to obtain full paper
copies of and which trials to include a solution will be
found by discussion between the review authors with
Christian Gluud arbitrating.
Data extraction and management
Two review authors (Henrik Steglich-Arnholm and
Markus Holtmannspötter) will independently extract
data from each eligible trial onto a standard designed
data extraction form. Review authors will not be blinded
to journal or institution. Disagreements will be resolved
by discussion among all authors.
The following data will be extracted from included
studies:
– First author
– Country of origin
– Trial design
– Inclusion and exclusion criteria
– Number of participants
– Patient characteristics
– Details of endovascular interventions used (including
methods for intraarterial clot removal/lysis,
antegrade or retrograde stenting approach,
angioplasty before/after stent placement, stents used,
etc.)
– Details of pharmacological therapy used (e.g.,
antiplatelet agent, dose, route of administration,
intravenous or intraarterial thrombolysis, etc.)
– Follow-up period
– Primary and secondary outcomes
– Adverse events
– Diagnostic criteria used for acute ischaemic stroke
(including whether MRI diffusion and perfusion
mismatch, CT-angiography or CT perfusion were
used to identify eligible patients)
– Co-interventions used (including type of
anaesthesia)
– Anatomy of arterial occlusions
– Time interval from stroke onset to procedure start
– Time interval from stroke onset to intracranial
recanalisation
– Time interval from procedure start to recanalisation
– Numbers of patients in each group with outcomes
– Patients lost to follow-up
Assessment of risk of bias in included studies
For randomised clinical trials the following domains will
be assessed for risks of bias: allocation sequence gener-
ation; allocation concealment; blinding of patients and
personnel; blinding of assessors; incomplete outcome
reporting; selective outcome reporting; industry bias;
and other apparent biases [46]. Domains will be assessed
according to these definitions:
Allocation sequence generation
– Low risk of bias: sequence generation is achieved
using computer generated random numbers or a
random number table, or similar.
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– Uncertain risk of bias: the trial is described as
randomised, but the method of sequence generation
is not specified.
– High risk of bias: the sequence generation method is
not, or may not be, random. Quasi-randomised
studies, those using dates, names, or admittance
numbers in order to allocate patients, are inadequate
and are excluded for the assessment of benefits but
not for assessing harms.
Allocation concealment
– Low risk of bias: allocation is controlled by a central
and independent randomisation unit, sequentially
numbered, opaque and sealed envelopes, or similar,
so that intervention allocations cannot be foreseen
in advance of or during enrolment.
– Uncertain risk of bias: the trial is described as
randomised but the method used to conceal the
allocation is not described, so that intervention
allocations may be foreseen in advance of or during
enrolment.
– High risk of bias: if the allocation sequence is known
to the investigators who assigned participants or if
the study is quasi-randomised. Quasi-randomised
studies are excluded for the assessment of benefits
but not for assessing harms.
Blinding of participants and personnel
– Low risk of bias: it is mentioned that both the
participants and personnel providing the
interventions were blinded, and the method of
blinding is described, so that knowledge of allocation
is prevented during the trial.
– Uncertain risk of bias: it is not mentioned if the trial
was blinded, or the trial is described as blinded, but
the method or extent of blinding is not described, so
that knowledge of allocation was possible during the
trial.
– High risk of bias: the trial is not blinded, so that the
allocation was known during the trial.
Blinded outcome assessment
– Low risk of bias: outcome assessment was carried
out blinded for all relevant outcomes, and the
method of blinding is described, so that knowledge
of allocation was prevented.
– Uncertain risk of bias: blinding of outcome
assessment is not described, or the outcome
assessment is described as blinded, but the method
of blinding is not described, so that knowledge of
allocation was possible.
– High risk of bias: outcome assessment is not
blinded, so that the allocation was known to
outcome assessors.
Incomplete outcome data
– Low risk of bias: the numbers and reasons for
dropouts and withdrawals in all intervention groups
are described, or if it is specified that there are no
dropouts or withdrawals.
– Uncertain risk of bias: the report gives the
impression that there have been no dropouts or
withdrawals but this is not specifically stated.
– High risk of bias: the number of or reasons for
dropouts and withdrawals are not described.
Selective outcome reporting
– Low risk of bias: pre-defined or clinically relevant
and reasonably expected outcomes are reported
on.
– Uncertain risk of bias: not all pre-defined or clinic-
ally relevant and reasonably expected outcomes are
reported on, or are not reported on fully, or it is un-
clear whether data on these outcomes are recorded
or not.
– High risk of bias: one or more clinically relevant and
reasonably expected outcomes are not reported on;
data on these outcomes are likely to have been
recorded.
Industry bias
– Low risk of bias: the trial appears to be free of
industry influence that could put it at risk of bias.
The trial did not receive direct financial support,
products for use in the trial, or funding for conduct
of trial tasks (e.g., analysis of data) from any parties
that might had conflicting interest (e.g., a drug or a
device manufacturer).
– Uncertain risk of bias: the trial may or may not
be free of industry bias that could put it at risk
of bias or did not provide financial disclosure
statements.
– High risk of bias: the trial is not considered free of
industry involvement.
Other bias
– Low risk of bias: the trial appears to be free of other
components that could put it at risk of bias.
– Uncertain risk of bias: the trial may or may not
be free of other components that could put it at
risk of bias.
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– High risk of bias: there are other factors in the trial
that could put it at risk of bias, e.g., authors have
conducted other trials on the same topic, etc.
Trials with low risk of bias assessments in all of the
above mentioned domains are considered as having low
risk of bias. Trials with one or more domains that are
unclear or high risk of bias will be considered trials with
high risk of bias [47].
Observational studies will be evaluated according to
the ACROBAT-NRSI tool for both cohort-type studies
and case-control-type studies [48].
Measures of treatment effect
Odds ratio with 95% confidence interval will be reported
for dichotomous outcomes. Mean differences or standar-
dised mean differences with 95% confidence interval will
be reported for continuous outcomes.
For each trial, a table describing the types of serious
adverse events reported will be presented.
Unit of analysis issues
Dealing with missing data
In the case of missing data, the authors of the original
trials and studies will be contacted in attempt to obtain
further details.
Intention-to-treat analyses
Incomplete or missing outcome data will be imputed
according to extreme case scenarios [49]:
– ‘Worst-best’ case scenario—extreme case analysis
favouring the experimental intervention. All the
missing event-data from the experimental group, but
none of the missing event-data from the control
group will be imputed as a bad outcome.
– ‘Best-worst’ case scenario—extreme case analysis
favouring the control. None missing event-data from
the experimental group, but all of the missing event-
data from the control group will be imputed as a
bad outcome.
Assessment of heterogeneity
Heterogeneity will be assessed quantitatively with
Cochran Q and I2 statistics as well as qualitatively.
Furthermore, fixed- and random-effects models will be
compared (see below).
Assessment of reporting biases
Funnel plots will be used for assessing reporting and
other types of bias. These plots will be assessed for
asymmetry qualitatively. If more than 10 studies are in-
cluded in the meta-analyses, funnel plots will also be
assessed for asymmetry quantitatively as follows.
Continuous outcomes with intervention effects measured as
mean differences
Funnel plot asymmetry will be assessed with a linear re-
gression approach suggested by Egger et al. [50]. In this
graphical approach, the mean difference of each study is
divided by its standard error and plotted against the in-
verse of its standard error. Smaller studies should have
larger standard errors and intercept trough (0,0). If this
line does not intercept in zero, then there is a risk of a
small-study effect and possible bias. Furthermore, the
slope of this line will indicate the size and direction of
the intervention effect.
Dichotomous outcomes with intervention effects measured
as odds ratios
For dichotomous outcome measures, the above men-
tioned method is not feasible for estimating a small-
study effect because the estimates of the effect size and
of the standard error are correlated.
Therefore, if there is a low between-study hetero-
geneity (τ2 < 0.1), a modified version of the linear re-
gression method mentioned above will be used. In
this version, an efficient score is plotted against a
score variance which is not correlated. These esti-
mates are calculated from number of events and par-
ticipants in the control and intervention group and
the total number of participants [51].
On the other hand, if there is not low between-study
heterogeneity (τ2 ≥ 0.1), an arcsine transformation of
event-fractions can stabilise variances (study precision)
and a heterogeneity parameter is introduced in the re-
gression model. This allows testing for small-study ef-
fects with sufficient power even when substantial
heterogeneity is present [52].
Data synthesis
Meta-analyses will be performed according to the rec-
ommendations of the Cochrane Handbook for System-
atic Reviews of Interventions [46]. For the statistical
analyses, Review Manager 5.3 (Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2014),
SAS software version 9.4 (SAS Institute Inc., Cary, NC,
USA), and Trial Sequential Analysis version 0.9
(Copenhagen Trial Unit, Centre for Clinical Intervention
Research, Rigshospitalet, Copenhagen, Denmark;
www.ctu.dk/tsa) will be used.
Trial sequential analyses
Conventional meta-analysis methods usually only assess
statistical significance of the intervention effect from the
accrued evidence in a review and lack assessment of the
amount of evidence behind these effect estimates. Such
assessment is available through Trial Sequential Analysis
methods. Trial Sequential Analyses will control the risk
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of random errors due to sparse data and potential repeti-
tive analyses of data and prevent premature statements
of superiority of the experimental or control interven-
tion or premature statement of futility [53, 54]. Trials
will be included in the sequential analysis one by one
and ultimately checked if predefined two-sided signifi-
cance testing- or futility boundaries are crossed and if
the diversity-adjusted required information size is
reached [55]. The diversity-adjusted required informa-
tion size for dichotomous outcomes will be calculated
for the primary and secondary outcomes on the basis of
the proportion of outcomes in the control group, a rela-
tive risk reduction of 20% as well as the relative risk in
randomised clinical trials with low risks of bias (if such
trials can be identified), a type I error of 2.5%, a type II
error of 20% (80% power), and the diversity of the meta-
analysis [56]. The type I error risk will be based on
Jakobsen and colleagues’ correction for multiplicity [57].
Finally, Trial Sequential Analyses will establish if suffi-
cient studies are identified in order to make firm conclu-
sions on the safety and efficacy of carotid artery stenting
in acute ischaemic stroke.
Assessments
Intervention effects will be assessed with both
random-effects model meta-analyses [58] and fixed-
effect model meta-analyses [59]. The more conserva-
tive point estimate of the two (the estimate closest to
no effect or the estimate with the widest confidence
interval) will be used [57]. Furthermore, each of the
eight steps proposed by Jakobsen and colleagues [57]
will be addressed to validate the results from the
meta-analyses.
The conclusion will primarily be based on results from
trials with low risk of bias in all domains and on the
primary outcomes after 3 months.
Subgroup analysis
The following subgroup analyses are planned:
– Trials with low risk of bias compared to trials with
high risk of bias
– Trials assessing preparatory carotid stenting
compared to trials assessing carotid stenting after
thrombectomy
– Trials compared according to type and dosage of
antiplatelet regimen used
– Trials assessing the combination of intravenous
thrombolysis with single or dual antiplatelet therapy
administered during the intervention compared to
trials using no concomitant thrombolysis and
antiplatelet therapy
– Trials assessing pre- and/or post-stenting angioplasty
in patients with carotid stenting
– Trials assessing level of anaesthesia (general
anaesthesia or conscious sedation) for patients with
carotid stenting as well as patients without carotid
stenting
‘Summary of findings’ table
To minimise incorrect interpretations of findings and rec-
ommendations, a ‘summary of findings’ table [46] will be
constructed for all outcomes using GRADEprofiler
(https://gradepro.org/). The Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) ap-
proach appraises the quality of a body of evidence based
on the extent to which one can be confident that an esti-
mate of effect or association reflects the item being
assessed [60]. The quality of a body of evidence considers
within-study risk of bias, the indirectness of the evidence,
heterogeneity of the data, imprecision of effect estimates,
and risk of publication bias.
Discussion
This review will assess the benefits and harms of ex-
tracranial carotid stenting versus no stenting in acute
ischaemic stroke patients treated with thrombectomy
for ipsilateral intracranial occlusions. Endovascular
therapy was recently implemented in the American
Heart Association guidelines for treating acute ischae-
mic stroke caused by an intracranial large vessel oc-
clusion [26]. However, our preliminary searches have
suggested only limited evidence for acute carotid
stenting during endovascular management of a large
intracranial occlusion in observational studies. A thor-
ough assessment of the evidence for carotid stenting
in this setting is needed to guide clinicians in this
therapeutic conundrum.
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